CN107595771A - 注射用缓释制剂 - Google Patents

注射用缓释制剂 Download PDF

Info

Publication number
CN107595771A
CN107595771A CN201710826880.1A CN201710826880A CN107595771A CN 107595771 A CN107595771 A CN 107595771A CN 201710826880 A CN201710826880 A CN 201710826880A CN 107595771 A CN107595771 A CN 107595771A
Authority
CN
China
Prior art keywords
solution
formulation
active ingredient
injection
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710826880.1A
Other languages
English (en)
Chinese (zh)
Inventor
中川隆
小关宣雅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CN107595771A publication Critical patent/CN107595771A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201710826880.1A 2010-10-18 2011-10-18 注射用缓释制剂 Pending CN107595771A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39406910P 2010-10-18 2010-10-18
US61/394069 2010-10-18
CN201180060225.0A CN103249416B (zh) 2010-10-18 2011-10-18 注射用缓释制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180060225.0A Division CN103249416B (zh) 2010-10-18 2011-10-18 注射用缓释制剂

Publications (1)

Publication Number Publication Date
CN107595771A true CN107595771A (zh) 2018-01-19

Family

ID=45933169

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710826880.1A Pending CN107595771A (zh) 2010-10-18 2011-10-18 注射用缓释制剂
CN201180060225.0A Expired - Fee Related CN103249416B (zh) 2010-10-18 2011-10-18 注射用缓释制剂
CN201710826877.XA Pending CN107625728A (zh) 2010-10-18 2011-10-18 注射用缓释制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201180060225.0A Expired - Fee Related CN103249416B (zh) 2010-10-18 2011-10-18 注射用缓释制剂
CN201710826877.XA Pending CN107625728A (zh) 2010-10-18 2011-10-18 注射用缓释制剂

Country Status (7)

Country Link
US (3) US9469630B2 (https=)
EP (1) EP2629775A4 (https=)
JP (4) JP5893616B2 (https=)
KR (1) KR101936968B1 (https=)
CN (3) CN107595771A (https=)
CA (1) CA2814840C (https=)
WO (1) WO2012053654A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
WO2014084921A1 (en) * 2012-11-27 2014-06-05 Rose Stuart Pharmaceutical manufacturing method and compositions
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
WO2016044649A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
KR101792414B1 (ko) * 2016-05-19 2017-11-01 삼성전기주식회사 박막 커패시터 및 그 제조방법
CN105963253A (zh) * 2016-06-19 2016-09-28 朱武欣 一种罗替戈汀长效水性混悬型注射剂
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
CA3034995A1 (en) * 2016-08-31 2018-03-08 Sumitomo Dainippon Pharma Co., Ltd. Aqueous suspension preparation
US10252229B2 (en) * 2017-06-30 2019-04-09 Snowie LLC System comprising a pump attached to a tank casing for mixing a fluid
SG11202008233WA (en) 2018-02-28 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Aqueous suspension pharmaceutical preparation with controlled dissolution
SG11202008204QA (en) * 2018-02-28 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Aqueous suspension pharmaceutical preparation
JP7214103B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JPWO2020179925A1 (https=) * 2019-03-07 2020-09-10
CN110478131B (zh) * 2019-08-05 2022-01-11 思必康（厦门）新材料有限公司 一种pH响应变色的纱布及其制备方法和该纱布的应用
US11041740B1 (en) 2019-12-20 2021-06-22 EmpNia Inc. Method and apparatus for real time respiratory gating signal generation and detection of body deformation using embedded fiber Bragg gratings
CN119431400A (zh) * 2020-03-27 2025-02-14 波士顿科学国际有限公司 用于使药物结晶的方法
EP4196106A1 (en) * 2020-08-11 2023-06-21 Auxilla Pharmaceuticals and Research LLP A non-aqueous suspension of anticancer agent
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
JP2024511693A (ja) 2021-03-31 2024-03-15 四川科▲倫▼▲薬▼物研究院有限公司 注射可能なルラシドン懸濁液及びその製造方法
CN120078778A (zh) * 2024-09-25 2025-06-03 山东百诺医药股份有限公司 一种伏硫西汀酯药物组合物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1216991A (zh) * 1996-05-07 1999-05-19 美国辉瑞有限公司 5－(2－(4－(1,2－苯并异噻唑－3－基)－1－哌嗪基)乙基)－6－氯－1,3－二氢－2(1h)－吲哚－2－酮(=ziprasidone)的甲磺酸盐二水合物,它的制备及其作为多巴胺d2拮抗剂的用途
JP2003160583A (ja) * 2001-11-27 2003-06-03 Sumitomo Chem Co Ltd イミド誘導体の製造方法
CN1832946A (zh) * 2003-07-29 2006-09-13 大日本住友制药株式会社 生产酰亚胺化合物的方法
CN1845721A (zh) * 2003-08-06 2006-10-11 阿尔克姆斯第二控制治疗公司 阿立哌唑的给药方法
CN101198331A (zh) * 2005-06-13 2008-06-11 大日本住友制药株式会社 增溶化制剂
RU2342927C2 (ru) * 2003-10-23 2009-01-10 Оцука Фармасьютикал Ко., Лтд Стерильный состав для инъекций с контролируемым высвобождением, содержащий арипипразол, и способ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
KR100537713B1 (ko) 1997-09-30 2005-12-20 일라이 릴리 앤드 캄파니 2-메틸-티에노-벤조디아제핀 제제
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
FI105074B (fi) 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
PL196821B1 (pl) 1998-09-30 2008-02-29 Lilly Co Eli Sól olanzapiny i jej zastosowanie
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
DE10218110A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
AU2005307797B2 (en) 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
CN101166514A (zh) 2005-04-13 2008-04-23 辉瑞产品公司 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法
CN102048734B (zh) * 2005-05-26 2013-11-20 大日本住友制药株式会社 药物组合物
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007106768A2 (en) 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
WO2009074666A1 (en) 2007-12-13 2009-06-18 Novartis Ag Organic compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1216991A (zh) * 1996-05-07 1999-05-19 美国辉瑞有限公司 5－(2－(4－(1,2－苯并异噻唑－3－基)－1－哌嗪基)乙基)－6－氯－1,3－二氢－2(1h)－吲哚－2－酮(=ziprasidone)的甲磺酸盐二水合物,它的制备及其作为多巴胺d2拮抗剂的用途
JP2003160583A (ja) * 2001-11-27 2003-06-03 Sumitomo Chem Co Ltd イミド誘導体の製造方法
CN1832946A (zh) * 2003-07-29 2006-09-13 大日本住友制药株式会社 生产酰亚胺化合物的方法
CN1845721A (zh) * 2003-08-06 2006-10-11 阿尔克姆斯第二控制治疗公司 阿立哌唑的给药方法
RU2342927C2 (ru) * 2003-10-23 2009-01-10 Оцука Фармасьютикал Ко., Лтд Стерильный состав для инъекций с контролируемым высвобождением, содержащий арипипразол, и способ
CN101198331A (zh) * 2005-06-13 2008-06-11 大日本住友制药株式会社 增溶化制剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
TAKEO ISHIYAMA , KUMIKO TOKUDA, TADASHI ISHIBASHI, AKIRA ITO,SAT: "Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *
塔苏等: "《纳米粒药物输送系统》", 30 September 2010, 北京大学医学出版社 *
易红，高进，杨华，孙晖: "几种注射用表面活性剂的质量标准及安全性概述", 《中国实验方剂学杂志》 *
杨臻峥; 孙大柠: "抗精神病药Lurasidone Hydrochloride", 《药学进展》 *
潘卫三主编: "《工业药剂学》", 30 June 2010, 中国医药科技出版社 *

Also Published As

Publication number Publication date
CA2814840C (en) 2018-08-28
CN103249416B (zh) 2019-06-04
JP6173502B2 (ja) 2017-08-02
US20190010149A1 (en) 2019-01-10
KR20130139978A (ko) 2013-12-23
CN103249416A (zh) 2013-08-14
JP5893616B2 (ja) 2016-03-23
EP2629775A4 (en) 2014-06-11
KR101936968B1 (ko) 2019-01-09
JP2013543481A (ja) 2013-12-05
US20160158228A1 (en) 2016-06-09
JP2019006822A (ja) 2019-01-17
US9469630B2 (en) 2016-10-18
CA2814840A1 (en) 2012-04-26
JP2016128503A (ja) 2016-07-14
JP6410889B2 (ja) 2018-10-24
JP2017206543A (ja) 2017-11-24
EP2629775A1 (en) 2013-08-28
WO2012053654A1 (en) 2012-04-26
CN107625728A (zh) 2018-01-26
US20120091022A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
CN107595771A (zh) 注射用缓释制剂
US9545457B2 (en) Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
AU2010325632B2 (en) Process for preparing pharmaceutical ophthalmic compositions
JP2007532619A (ja) 懸濁したガラス粒子を含有する液体
JP2013543481A5 (https=)
JP2013512894A5 (https=)
KR101843613B1 (ko) 약제학적 페메트렉시드 액제
CN107349181B (zh) 含有瑞巴派特和聚维酮的眼科水悬浮液及其制备方法
MD3769753T2 (ro) Procedeu de preparare a suspensiilor de nanocristale de propionat de fluticazonă Forma A apoase oftalmice sterile
NO880403L (no) Parenterale suspensjoner.
JP2025024083A (ja) 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液
CN107233583A (zh) 一种具有超长持续时间的超声造影剂及其制备方法
CA3268119A1 (en) Sterilized heterocyclidene-acetamide-derivative-containing suspension
TWI584823B (zh) 具有延長的保存期限的阿立哌唑可注射懸浮液製劑
WO2021199076A1 (en) Injectable aripiprazole formulation
Nail et al. Coarse suspensions: design and manufacturing
WO2011016435A1 (ja) ポリ乳酸粒子含有凍結乾燥組成物の製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180119

WD01 Invention patent application deemed withdrawn after publication